cytochrome b5 type AGenealiases: CYB5 · MCB5 · METAG
Q-omics provides the consensus-scored CYB5A profile across patient tissues and cancer cell-line models. CYB5A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CYB5A is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CYB5A RNA expression shows 18,919 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where CYB5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5A survival associations across molecular data types. CYB5A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5A RNA expression–survival associations across cancer types. High CYB5A expression shows favorable associations in MESO, KIRC, KIRP, COAD, LIHC and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CYB5A RNA expression.
This table summarizes CYB5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CYB5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5A shows lower tumor expression in KICH, LUAD, KIRP, LUSC and THCA and higher tumor expression in KIRC. The KICH box plot shows higher CYB5A RNA expression in normal versus tumor tissue (log2 FC = −2.581, t-test p < 0.001).
This table shows molecular features associated with CYB5A in patient tissues and cancer cell lines. In patient samples, CYB5A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
